PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Celadon receives good manufacturing practice approval

MHRA approval relates to the company’s midlands-based drug development facilities.

Celadon – a company focused on the development of cannabis-based medicines – has announced that its midlands-based UK facility has now been registered by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the Good Manufacturing Practice (GMP) manufacturing of its cannabis active pharmaceutical ingredient (API).

GMP is the globally recognised quality standard required to manufacture pharmaceutical medicines for clinical trials and human use. The approval is a compulsory requirement for the commercialisation of Celadon’s medicinal cannabis product, which is supplied in oil form as an API.

Celadon’s API is manufactured using a combination of genetics, extraction technology and indoor hydroponic cultivation. Incorporating a controlled environment, cultivation allows Celadon to achieve pharmaceutical-level consistency and replicability.

The company’s GMP product and its ongoing R&D programme have seen it partner with leading universities, government bodies and fellow pharmaceutical companies undertaking cannabinoid research and drug development.

James Short, chief executive officer at Celadon, reflected: “With the receipt of GMP registration, Celadon has joined a very select group of cannabis-focused pharmaceutical companies globally. This is a tremendous milestone for the company given the significant capital and regulatory requirements in this sector.”

He added: “Today’s announcement is the culmination of four years of hard work. I would like to thank the team and our loyal shareholders for their support and belief in our vision as we continue our journey of putting the patient first in ensuring they can access the cannabis-based medicines they so desperately need.”

Celadon’s current home office licence permits it to legally grow medicinal cannabis for the purpose of producing test batches of cannabis oil to support its application to the MHRA. While there is no guarantee that the home office will update the current licence, nor any timeframe for this, the company’s directors are confident that the licence will be updated in due course.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026